Longevity Science Foundation

We’re thrilled to announce a grant awarded to the researchers at the Department of Physiology, Anatomy & Genetics - University of Oxford for their study, “Metabolic Mechanisms of Ageing in the Heart - Novel Dietary Interventions for Enhancing Healthspan." Led by Prof. Pawel Swietach and co-supervised by Dr. Richard Siow, the research explores how metabolism, particularly changes in methylation related to diet, influences heart aging and aims to identify potential therapies for heart disease, which is one of the leading causes of death globally. The 3-year project will not only advance our understanding of the heart health but also offer invaluable training opportunities to the next generation of researchers in aging and #longevity. As we continue building partnerships with the University of Oxford, we look forward to funding more pioneering research and driving impactful advancements in human longevity. Read the full announcement: https://lnkd.in/dPMnBMae

An important update: the agenda for the 6th ARK Longevity Week Symposium, hosted in collaboration with European Society of Preventive Medicine and The Longevity Forum, is now live! We’re excited to share that our President & CEO, Joshua Herring, will be joining virtually. A major announcement will also be made at the event. Stay tuned for details! Check the Ageing Research at King's College London (ARK-AI)'s website to view the full event agenda: https://lnkd.in/d8kR6GQr

Join us for the 6th Longevity Week event at King's College London, hosted by Ageing Research at King's College London (ARK-AI) in partnership with the European Society of Preventive Medicine (ESPM) and the Longevity Science Foundation (LSF)! The symposium, "Longevity - Preventive Medicine Across the Lifespan," is a part of the Longevity Week series by The Longevity Forum. Our parters at ARK are bringing together top experts to discuss innovative strategies in preventive medicine for healthy aging. From cutting-edge technologies to integrated data analytics, the speakers will explore how preventive care, lifestyle interventions, and health monitoring can help us all live longer, healthier lives. Check the event link for more details: https://lnkd.in/d8kR6GQr

New research on heart aging receives major grant from LSF University of Oxford team to study dietary interventions for improving cardiac health and extending lifespan with Longevity Science Foundation’s support. Joshua Herring #investment #research #cardiachealth #longevity

As you might know, earlier this month, I made a significant shift in my career and stepped in as President & CEO of the Longevity Science Foundation (LSF), a global 501(c)(3) nonprofit. I want to re-emphasize our mission, the powerful impact we're striving to make through our grant funding, and call on members of my community to get involved and #donate today. Global aging is reshaping the world, with adults over 60 becoming the fastest-growing demographic worldwide. This shift will have a profound impact on our healthcare, workforce, and economic systems. Societally, one of our focuses must be extending the number of years people live without debilitating diseases and chronic conditions: our healthy #longevity. Achieving this requires a significant investment in research on biological aging and disease prevention for chronic and age-related ailments. At the LSF we partner with the globe’s brightest minds, granting much-needed capital to teams, whose work will have a profound impact on our understanding of aging and how to do so as healthily as possible. We have already received highly promising proposal submissions from diverse scientific teams, including top-tier universities and independent research collectives. One of the projects we are currently funding is a transformational study of heart health and aging at the Department of Physiology, Anatomy & Genetics - University of Oxford, as deaths linked to heart disease account for nearly one-third of all mortality. Transparency is at the heart of what we do. Donors can choose to support a specific research project or spread their contributions across several pre-vetted applications, carefully reviewed by our outstanding Scientific Advisory Board, the key opinion leaders in longevity medicine and biotech: Evelyne Bischof, MD, PhD, Matt Kaeberlein, Michael Levitt, Andrea B. Maier, Eric Verdin, Alex Zhavoronkov. Key points to consider: Access to Capital: We provide essential funding to capital-constrained projects, ensuring innovative longevity research has the resources it needs to make a real-world impact. Donation Power: Every contribution, no matter the size, can create significant change in creating accessible longevity medicine for all. 100% to the Cause: I’m proud to announce that for this round of fundraising, we have gained support from our Board of Directors that the next 100% of the next $100,000 raised will go directly to our selected projects, with no funds allocated to operating or administrative costs. This means that your donations will go entirely toward advancing the science we support. With all of that said, if you are interested in making a donation to the LSF, please use the following link: https://lnkd.in/eJWfGuX8 If you are interested in what we do as an organization and would like to learn more, please feel free to reach out to me directly at jh@longevity.foundation.

We are announcing a leadership transition at the Longevity Science Foundation. After nearly two years as President & CEO, Lisa Ireland is stepping down, having established the LSF as a key player in the longevity biotech field. We express gratitude to Lisa for her impactful leadership, and we welcome Joshua Herring as our new President & CEO, who will carry the torch forward and guide us into the next chapter of promoting cutting-edge longevity research and innovation. Read more: https://lnkd.in/d3YHH2gP

A great overview of the 2024 Aging Research & Drug Discovery Meeting from our colleagues at LongeVC ⬇️

The 11th Annual Aging Research & Drug Discovery Meeting (ARDD) conference has ended last Friday. The five-day summit on biological aging and human #longevity, held at the Københavns Universitet - University of Copenhagen, was packed with inspiring presentations, panels, and keynotes from leading experts in longevity biotech and beyond. Our Co-Founders, Garri Zmudze and Sergey Jakimov, took part in the investors' and start-up pitch judges’ panels respectively, while our Scientific Advisors, Evelyne Bischof, MD, PhD, Andrea B. Maier, Eric Verdin, and Alex Zhavoronkov, delivered insightful talks on aging research and medicine. We are immensely proud of our longstanding ties with ARDD, and we thank to the event chairs Alex Zhavoronkov, Morten Scheibye-Knudsen, Daniela Bakula and Evelyne Bischof, MD, PhD for organizing such a fantastic conference! #ARDD #ARDD2024 *kudos to Eugen Chirita for photography

The 11th Aging Research & Drug Discovery conference has began! Evelyne Bischof, MD, PhD is leading the opening ceremony for the Longevity Medicine Track and the XPRIZE Healthspan Team Summit. ARDD brings together leading scientists, physicians, and investors in the #longevity biotech space. Check the link for more information: https://lnkd.in/djawW5Y3 #ardd #ardd2024

Brain health is one of the bottlenecks of the goal of living longer. A recent breakthrough gets us a bit closer to brain longevity 🔬 As we age, the brain’s glymphatic system, responsible for clearing out toxic waste, deteriorates. This leads to a buildup of harmful proteins that contribute to neurological disorders like Alzheimer’s and Parkinson’s. Some even refer to Alzheimer’s, and Parkinson’s as “dirty brain” diseases. Scientists at the University of Rochester have discovered that a drug commonly used to induce labor can also restore the brain’s waste disposal system in aging brains, potentially opening new avenues for treating neurological disorders like Alzheimer’s and Parkinson’s disease. Key Takeaways: The drug, prostaglandin F2α, enhances the contraction of cervical lymph vessels, crucial for draining waste from the brain. This drug restored waste-clearing efficiency in older mice to levels comparable to younger animals. The research highlights the role of the brain’s glymphatic system, which slows down with age, leading to toxic protein buildup. NOTE: this research has been conducted in mice, so it is still unclear if it can be used in humans! Since I’ve touched upon aging research in this post, let me also remind you about the upcoming 11th Aging Research and Drug Discovery Conference (#ARDD2024), which is just several days away from now! 🚀 I will be participating in an investor panel “How do we build a longevity biotechnology industry?” moderated by Lisa Melton from Nature Biotechnology. Happy to be alongside such great industry leaders as Lars Hartenstein McKinsey Health Institute, USA, Michael Baran Pfizer, Inc., USA, Petr Sramek, Healthy Longevity Clinic, Marie Kveiborg Novo Nordisk Foundation, Jacob Hanna Weizmann Institute of Science, Israel, and Alex Zhavoronkov, Insilico Medicine Drop a line to BAKULA@sund.ku.dk for more information on how to participate. #aging #brainhealth #research #breakthrough Alex Zhavoronkov Morten Scheibye-Knudsen Daniela Bakula Evelyne Bischof, MD, PhD Longevity Science Foundation Image credit: Nature Aging